momentum acceler
illumina earn check almost everi box look
upgrad overweight quarter highlight revenu
growth y/i come forecast beat broad-bas led
servic revenu y/i beat consum revenu acceler
tougher comp y/i beat better expect regardless
stock order novaseq consum specif grew q/q
estim pull-through around per instrument top-lin beat drove
signific ebit beat vs forecast upsid beat higher margin
recur revenu total led gross margin beat
acceler invest sale could keep pace revenu
drove oper margin beat adj ep beat forecast
street
believ share still screen attract due multipl factor rais
price first see long runway higher novaseq
util custom proprietari novaseq survey weight average
consum pull-through well current level survey also
confirm view novaseq repres multi-year adopt cycl
compani custom expect scale time second see potenti
upsid popul sequenc custom nih us initi
million genom expect begin data gener year end third
continu see encourag traction clinic custom think april
coverag decis base diagnost could repres catalyst adopt
final continu see long runway growth china repres
sale grew y/i combin factor improv
convict drive mid-teen growth next sever year
model compound-annual-growth-rate outsiz growth higher-margin recur
revenu categori allow leverag top line growth drive faster
earn growth high-teen model compound-annual-growth-rate new
guidanc good job exemplifi phenomenon forecast
revenu growth adj ep growth midpoint reiter
quarterli annual ep usd
rais usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
overweight leader next
gener sequenc project
signific growth driven larg research studi
nascent opportun clinic diagnost
signific competit moat rel
competit given brand scale
growth forseeabl futur
compani instal base grow higher
consum revenu contribut margin
leverag estim upsid case
reflect upsid ep
growth ultim depend
custom fund includ govern grant
nih well clinic reimburs lower
downsid case reflect downsid
ep
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
illumina earn check almost everi box look
upgrad overweight proprietari novaseq survey say elast
upgrad ow quarter highlight revenu growth y/i come
forecast beat broad-bas led servic revenu y/i
beat driven popul sequenc nipt consum test servic
consum revenu acceler tougher comp y/i beat
better expect regardless stock order novaseq consum
specif grew q/q estim pull-through around per
instrument top-lin beat drove signific ebit beat vs forecast
upsid beat higher margin recur revenu total led gross
margin beat acceler invest sale could keep pace
revenu drove oper margin beat adj ep beat forecast
street ep beat benefit lower
expect tax rate vs model hope obviou
tertiari driver beat
believ share still screen attract due multipl factor rais price
first see long runway higher novaseq util
custom proprietari novaseq survey weight average consum pull-through
well current level survey also confirm view
novaseq repres multi-year adopt cycl compani custom expect
scale time second see potenti upsid popul sequenc
custom nih us initi million genom expect begin data
gener year end third continu see encourag traction clinic
custom think april coverag decis base diagnost could
repres catalyst adopt final continu see long runway growth
china repres sale grew y/i combin
factor improv convict drive mid-teen growth
next sever year model compound-annual-growth-rate outsiz growth higher-
margin recur revenu categori allow leverag top line growth
drive faster earn growth high-teen model compound-annual-growth-rate
new guidanc good job exemplifi phenomenon forecast
revenu growth adj ep growth midpoint reiter
increas price target given higher earn forecast
convict potenti upsid driven novaseq demand price target
repres adj ep forecast target multipl base
histor ratio earn growth project high-teen forseeabl
futur prior price target repres prior adj ep forecast
histor valuat price earn yr earn growth yr compound-annual-growth-rate
follow strong result rais revenu ep guidanc
compani expect revenu growth prior guidanc
growth increas revenu guidanc driven stronger expect
sequenc consum specif relat novaseq remind compani
embed mileston relat payment associ recent loxo oncolog
bristol-my squibb collabor consist previou guidanc expect
place novaseq non-gaap ep expect rang
midpoint prior guidanc midpoint ep guidanc
repres growth y/i ep guidanc includ dilut helix
addit oper expens anticip slightli lower y/i follow
modest benefit helix invest anticip non-
tax rate go forward expect non- tax rate
compani expect share count million
expect revenu flat slightli revenu advers
impact pull-forward million chines stock order result
compani expect modest sequenti increas
sequenc consum
sequenc instrument revenu also expect grow result season array
revenu expect declin sequenti return growth gross
margin expect declin modestli oper expens anticip
increas sequenti basi due hire invest plan impact fx
expect smaller
reiter novaseq placement expect expect
compani place instrument bring cumul number novaseq
placement includ million stock order mostli novaseq
novaseq consum grew roughli million sequenti demand
driven strength compani flow cell demand flow cell
launch februari continu ramp continu confid
novaseq expand whole-genom sequenc market note consum
spend user run hiseq novaseq expand compani
still believ earli stage replac cycl
approxim high throughput custom adopt novaseq
regard futur desouza note compani continu expect place
novaseq
model forecast novaseq placement averag
consum pull-through follow expect placement
assum novaseq place repres replac least
one hiseq compani start see cannib hiseq custom well
given rel advantag novaseq forecast million novaseq
revenu year launch compar million nextseq
revenu million hiseq revenu year launch
assumpt model place novaseq per year hiseq
hiseq decommiss persist beyond given multi-year adopt util
increas per novaseq end model million
survey averag sinc assum new custom add lower overal average
guidanc growth gross marginup modestli modestli y/yup slightli y/ynon-gaap op base per sharenon-gaap interest extinguish debtleg contingenciescost-method investmentsconting compensationheadquart relocationothergaap barclay illumina inc
barclay research revenu build
pleas see survey
say elast
upgrad ow
remind survey march-april show signific
demand novaseq continu expect major custom transit toward
platform custom spoke broadli expect de-commiss
hiseq hiseq instal base novaseq addit replac least
instrument across board shown novaseq instal base custom
spoke expect doubl today next year
segmentarray y/i miniseq instal y/i y/i stack y/i product y/i instrument instrument instrument instrument instrument miniseq instrument y/i y/i product product y/i product y/i servic y/i y/i consum instrument barclay illumina inc
expect lead signific reduct hiseq instrument
hiseq instrument collect decreas one custom transit
fleet nextseq onto novaseq instrument interestingli speak one
custom alreadi sold two novaseq anoth lab made
strateg pivot focu bioinformat cater custom buy novaseq
proprietari novaseq custom survey show major transit toward novaseq platform
novaseq custom survey expect substanti increas volum
sequenc next two year driven larg popul sequenc studi
increas cost effect exom sequenc substanti excit
around larg popul sequenc project sever referenc includ nih
us million genom initi us uk genom initi exom
grail liquid biopsi clinic trial could sequenc genom
regeneron announc would sequenc exom biobank
next month build volum total center survey describ
impli increas genom increas
exom collect number sampl
sequenc would increas anoth
custom proprietari survey expect volum growth
custom survey expect weight averag budget increas
custom expect budget declin next year broad
rang expect growth matur center project growth
rapidli grow sequenc custom project growth one smaller
research custom cite flat budget use novaseq cost save drive offset
amount volum coverag driver sequenc growth almost everi
custom use depth everi custom expect spend least million per
year consum novaseq weight averag million
believ unlik actual attain level overal instal base
averag sinc new custom addit drag overal novaseq averag
model project million novaseq util per instrument end
result self-report back envelop math suggest
decent approxim compar net instrument add decommiss
project novaseq util would suggest custom survey
increas consum spend gb sequenc
estim custom proprietari novaseq survey increas sequenc spend
revenu grew y/i million expect rel
expect better expect demand sequenc array
consum drove revenu beat geograph perspect growth
broad-bas quarter growth unit state growth emea
growth asia-pacif region specif shipment china
strength america emea result demand sequenc instrument
utilizationrev mmpull-through per inst per gbinstal base revsgb seq mm instal base revsgb seq mm revsgb yeary/i chang barclay illumina inc
revenu y/i growth
continu believ china long-term structur growth driver
life scienc research sequenc fit natur countri ambit tackl
long-term societ need transit industri economi servic
economi better compet market china repres
revenu dwarf larger economi like unit state
europ said market experienc signific growth
believ market sustain growth
next sever year eclips billion revenu
expect china drive substanti growth number year
revenu increas y/i million total revenu
consum grew quarter strength across low medium high
throughput analyz novaseq primari driver consum growth
quarter grow million sequenti inclus million one-tim stock
order see strong growth flow cell well solid ramp
flow cell launch februari nextseq util came
high end guid rang miseq miniseq util fell
within guidanc rang respect given on-going novaseq
upgrad cycl hiseq consum revenu declin y/i hiseq consum
remain healthi quarter instrument revenu declin y/i servic
revenu strong quarter grow y/i
novaseq high throughput sequenc platform custom focus whole-
genom sequenc advantag rel legaci hiseq hiseq product
line instal base hiseq hiseq instrument compani
address larg market opportun base instrument sale alon upsid
would driven market expans drive higher consum revenu
said placement cannib exist instrument consum opportun
would limit note consum cost per sampl like go
applic mean consum revenu could actual declin
per-box basi view launch make sens revolutionari
product aim drive replac cycl put rest concern
around revenu visibl near term long-term overcapac concern
like remain compani tri expand market beyond current instal
design system larg market opportun mind note
system allow highest-throughput achiev lower sequenc cost
much lower capit commit rel hiseq hiseq
compani believ architectur novaseq platform eventu
allow achiev genom system use newli develop
company/systemlaunchedinstru costrun costrun lengthrun speedthroughputpric per gbilluminaiseq fisher life ion day all-in n/an/abgi complet genomicsrevoloc ii long nanopor barclay illumina inc
flow cell allow higher-throughput increas speed-to-result
maintain accuraci earlier system compani launch novaseq
three flow cell option three flow cell throughout
capabl hiseq respect modestli
reduc speed-to-result hiseq day day novaseq
price capabl run three flow cell earn
announc cancel novaseq flow cell
custom primarili demand novaseq instrument
hiseq anticip demand hiseq weaker quarter custom
opt novaseq platform said compani note demand
hiseq remain strong quarter importantli focus
convert exist hiseq custom novaseq remind hiseq
launch per system januari announc
launch hiseq enhanc leverag capabl
hiseq system hiseq price reagent price
per gb similarli hiseq price provid half output
lower reagent costs/fast run time base commentari assum
util low end compani guid rang per
instrument hiseq consum expect trend downward throughout
hiseq launch novaseq plan drive replac cycl
hiseq custom come year launch hiseq
sequenc whole human genom compani market product
 sell ten instrument increas throughput larg genom center
reach covet genom price system million
note hiseq consum revenu declin million sequenti
quarter larg driven hiseq custom expect signific
replac cycl instrument follow recent launch flow cell
said compani note number custom need finish current
project upgrad
januari announc sell hiseq five system
configur known hiseq hiseq allow product center
adopt high-throughput whole genom sequenc lower capit invest
 full util set-up estim sequenc
genom year compani sell hiseq system million
addit hiseq xs million thereaft sequenc cost per gb
approxim versu hiseq
nextseq launch nextseq system fill nich product
portfolio hiseq miseq instrument product flex whole
human genom sequenc target panel price per system
estim compani place nextseq global pull-through
high end guid rang
also launch nextseq combin microarray scan
nextseq sequenc system initi array qualifi system
cytogenet pgd applic expect enabl broad rang
applic reproduct health genet health oncolog adapt
allow lab gain access array sequenc singl capital-expenditure
miseq miseq util fell within compani guid rang quarter sinc
launch miniseq encourag lower expect level
miseq cannib ultim believ market desktop
instrument minimum estim place though
could make argument market size product price
unit expect annual pull-through
miniseq/iseq launch januari miniseq compani smallest
benchtop sequenc design target sequenc applic smaller lab
cost instrument roughli believ pull number
quarter rang earli januari announc iseq
launch expand portfolio breadth lower-throughput end
sequenc market compani describ iseq inexpens fast easi
use sequenc iseq target address market potenti custom
rang current owner new-to- custom model current
instal base miniseq iseq instrument
iseq note shipment iseq began end ad
feedback instrument posit follow custom beta test
compani identifi opportun improv cartridg fill ship
process improv expect improv product robust
reliabl background announc iseq launch januari
expand portfolio breadth lower-throughput end sequenc
market view instrument nice addit portfolio though
addit growth vs high-throughput platform compani describ iseq
inexpens fast easi use sequenc iseq util best-in-
breed sequenc synthesi sb chemistri coupl complementari metal-
oxide-semiconductor cmo detect technolog iseq target address
market potenti custom rang current owner new-to-
custom iseq gener million read greater per
run run-tim rang hour price per sampl rang
addit sequenc cost less instal
custom less one hour
array revenu increas y/i quarter million strength driven
primarili consum servic respect instrument
revenu declin quarter remain smaller million
similarli recent trend demand driven strength direct-to-consum
market well global research applic includ genotyp epigenet
remind provid in-hous test servic dtc test compani notabl
ancestrydna compani also supplier dtc compani run volum in-
hous partner laboratori
gener revenu consum driven
strength array consum look back increas instal
base instrument market consum pull follow servic revenu
revenu grew y/i due mainten contract larger instal base
well strength sequenc servic lab
mix revenu instrument vs recur
gross margin improv y/i driven posit mix strength consum
easier comp compani non-gaap gross margin y/i
gross margin expect modestli keep mind
better margin consum revenu grew y/i revenu outpac
servic growth instrument revenu declin y/i ebitda margin
y/i
 declin y/i revenu ex-comp sg ex-comp
decreas y/i revenu result top line leverag total oper
expens sg stock-bas comp declin y/i revenu
helix account sg percentag revenu
non-gaap sg revenu
non-gaap ep increas y/i compani leverag strong top line
perform y/i margin improv deliv solid earn growth similar
compani tax rate benefit compani invest helix
result ep came estim fx provid
tailwind non-gaap ep quarter addit ep impact
dilut helix quarter independ tax benefit
quarterli non-gaap ep y/i growth
y/i growthnon-gaap epsepsy/i growth barclay illumina inc
 except ep reportedincom profit base ebitda ebit pre-tax pre-tax tax net net researchprior yearprior quarter barclay inc
estestestestestestestestestestincom statement growth growth growth growth growth growth y/i growth product revenu ex product revenu inc product revenu inc servic servic gross gross margin inc gross margin inc growth gener growth base sg stock base ebitda growth oper incom ebit growth invest debt expens pre-tax pre-tax growth incom tax non-control net net growth incom per basic ep inc non-cash growth interest net net growth growth net net net incom net barclay illumina inc
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
